What does the FDA approval of Casgevy for children under 12 mean?

The FDA has expanded Casgevy’s approval to include children as young as two with sickle cell disease or transfusion‑dependent β thalassemia. This marks growing regulatory confidence in CRISPR‑based therapies for younger patients and signals an important step toward earlier genetic interventions in hematology.